scholarly journals Liver Tolerance to Repeat 90Y-Microsphere Radioembolization

2008 ◽  
Vol 2 (2) ◽  
Author(s):  
Patrick McNeillie ◽  
Andrew S. Kennedy ◽  
William Dezarn ◽  
Scott L. Sailer ◽  
Mary England ◽  
...  
Keyword(s):  
Liver Function ◽  
Liver Tumors ◽  
Liver Volume ◽  
Dose Calculation ◽  
External Beam Radiation ◽  
Beam Radiation ◽  
Resin Microspheres ◽  
Life Threatening ◽  
Radiation Induced ◽  
And Function

Purpose: Liver tolerance to multiple doses of Y90-microspheres is not known. Many patients (pts) are surviving long enough to be considered for a second and third liver treatments with internal radiation. Materials and Methods: The experience of a single center treating liver tumors with resin Y90-microspheres. Pts that received liver radiation prior to or after resin microsphere therapy were studied. Endpoints were toxicity, tumor response, shunting to lung, and effects on liver volume and function. The delivery activity of microspheres selected was not reduced below BSA dose calculation for patients without prior treatment. All patients received bilobar single session delivery. Results: A total of 38 pts; 14 women, 24 men, treated 6∕2003 to 9∕2006, with 33 pts receiving 2 courses and 5 pts with 3 courses of liver radiation. Retreatment with resin microspheres 26 pts, prior external beam radiation in 7 pts, prior glass microspheres in 2 pts, prior systemic radiotherapy in 2 pts, and prior stereotactic liver radiation in 1 pt. Liver function was stable and adequate in all patients after additional liver radiation, and no pts developed radiation-induced liver dysfunction (RILD) or veno-occlusive disease (VOD). The percentage of shunting to the lung decreased with retreatment. Conclusions: Repeated implantation in the liver with Y90-microspheres is safe in patients that have sufficient liver function and reserve based on known and accepted laboratory parameters already used for selection of microsphere therapy. No acute life-threatening, fatal, or late liver damage was observed, RILD or VOD. No specific dose reduction is recommended for retreatment of the liver.

Repeat 90Y-microsphere radioembolization for hepatic malignancies: Safety and patient selection issues

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15177-15177
Author(s):  
A. S. Kennedy ◽  
W. A. Dezarn ◽  
P. McNeillie ◽  
M. England ◽  
C. Overton ◽  
...  
Keyword(s):  
Liver Function ◽  
Liver Tumors ◽  
External Beam Radiotherapy ◽  
Liver Volume ◽  
Latency Period ◽  
Normal Liver ◽  
External Beam Radiation ◽  
Unknown Primary ◽  
External Beam ◽  
Beam Radiation

15177 Background: Liver tolerance to reirradiation with multiple doses of 90Y-microspheres is not known. Many patients (pts) have also received external beam radiotherapy to the liver or through the liver and are surviving long enough to be considered for a second and third liver treatments with internal radiation. Methods: The experience of a single center treating liver tumors with resin 90Y-microspheres was used. Pts that received liver radiation prior to or after resin microsphere therapy were studied. Endpoints were toxicity, tumor response, disease type, latency period between radiation treatments, shunting to lung, and effects on liver volume and function. The delivery activity of microspheres selected was not reduced below that which was typically chosen for patients without prior liver radiation which was 25% reduced from the manufacturer’s BSA dose calculation method. All patients received bilobar microsphere delivery during a single session. Results: A total of 40 pts were identified; 14 women, 26 men, treated 6/2003 to 12/2006, with 35 pts receiving 2 courses and 5 pts with 3 courses of liver radiation. Retreatment with resin microspheres 26 pts, prior external beam radiation in 7 pts, prior glass microspheres in 2pts, prior systemic radiotherapy in 2 pts, and prior stereotactic liver radiation in 1 pt. Liver function was stable and adequate in all patients after additional liver radiation, and no pts developed radiation-induced liver dysfunction (RILD) or veno-occlusive disease (VOD). The percentage of shunting to the lung decreased with retreatment. Tumors treated: 14 carcinoid, 11 colorectal, 6 hepatocellular and cholangiocarcinoma, 2 sarcoma, 3 unknown primary, 1 each of breast, esophagus, and head and neck primaries. Conclusions: Repeated radiation to the liver with 90Y-microspheres appears safe in patients that have sufficient normal liver function and reserve based on known laboratory parameters already used for selection of microsphere therapy. No acute life-threatening, fatal, or late liver damage was observed, i.e. RILD or VOD. No specific dose reduction is recommended for retreatment of the liver. No significant financial relationships to disclose.

Comprehensive Analysis of the Kinetics of Radiation-Induced Lymphocyte Loss in Patients Treated with External Beam Radiation Therapy

2019 ◽  
Vol 193 (1) ◽  
pp. 73 ◽  
Author(s):  
Susannah G. Ellsworth ◽  
Anirudh Yalamanchali ◽  
Hong Zhang ◽  
Stuart A. Grossman ◽  
Robert Hobbs ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
External Beam Radiation Therapy ◽  
Comprehensive Analysis ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Radiation Induced ◽  
Kinetics Of

scholarly journals Can Tomato Powder Reduce Radiation-Induced Effects in a Murine Model of Prostate Cancer?

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 348-348
Author(s):  
Joe Rowles III ◽  
Matthew Wallig ◽  
Kimberly Selting ◽  
Timothy Fan ◽  
Rita Miller ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Inflammatory Markers ◽  
Cell Damage ◽  
External Beam Radiation ◽  
Surrounding Tissue ◽  
C Reactive Protein ◽  
Beam Radiation ◽  
Reactive Protein ◽  
Mouse Prostate ◽  
Radiation Induced

Abstract Objectives Tomatoes contain carotenoids and other potent antioxidants that may protect the surrounding tissue from the detrimental effects of external beam radiation therapy, while reducing rates of prostate carcinogenesis. The objective of this study was to determine whether dietary lyophilized tomato paste (TP) alters early inflammatory and oxidative events following a single dose of radiation and leads to a more successful therapeutic outcome. Methods Male Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice (n = 76) were provided a powdered AIN-93 G diet (Control) or a modified AIN-93 G diet containing 10% TP (w/w) at 4 weeks of age. Mice were monitored by ultrasound for in vivo tumor detection and 3-D volumetric measurement biweekly. Once tumors reached a volume of 1000 mm3, the caudal half of the mouse was irradiated with 7.5 gy (Rad, n = 18–19 per diet) or 0 gy (sham, n = 16–20 per diet) with a Cobalt-60 source. Mice were euthanized 24 hours after radiation or sham treatment. Antioxidants (carotenoids and α-tocopherol) were measured by high performance liquid chromatography (HPLC) in the serum, tumor, prostate, and liver. Sections of tumor, liver, kidneys, bladder, lymph, bladder and intestines were stained by hematoxylin and eosin (H&E) and cleaved-caspase 3 were assessed for radiation-induced changes and apoptosis. Inflammatory markers (C-reactive protein, IL-6, IL-17A, TNFα, IFNγ, and IL-10) were measured in serum, liver, prostate, tumor, and epididymal adipose tissues by ELISA. Results This study is the first to explore the effects of TP on the tumor microenvironment following irradiation. Initial results suggest that TP consumption does not alter circulating or tissue (liver and prostate) concentrations of inflammatory markers (C-reactive protein, TNFα, IFNγ, IL-6, IL-17, or IL-10). We hypothesize that TP-Rad will maintain similar levels of circulating concentrations of antioxidants (carotenoids and α-tocopherol) compared to sham-treated mice. Additionally, we hypothesize that TP will reduce markers of cell damage in surrounding tissues. Conclusions This study will provide important preclinical data to inform future clinical trials evaluating approaches to lessen extra-prostatic damage from radiation therapy and thus improve therapeutic outcomes. Funding Sources This work was supported by USDA NIFA ILLU-971–334.

scholarly journals COMPLICATIONS OF NEOADYAVANT THERAPY FOR CANCER OF THE HEAD OF THE PANCREAS

2019 ◽  
Vol 18 (3) ◽  
pp. 20-25
Author(s):  
R. I. Rasulov ◽  
M. V. Zemko ◽  
A. V. Shelekhov ◽  
K. G. Zubrinckiy ◽  
G. I. Songolov
Keyword(s):  
Radiation Therapy ◽  
Pancreatic Head ◽  
External Beam Radiation Therapy ◽  
Gastroduodenal Artery ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Pancreatic Head Cancer ◽  
Radiation Induced ◽  
Head Of The Pancreas

Aim: to study complications of preoperative chemoembolization of the gastroduodenal artery and external beam radiation therapy in patients with pancreatic head cancer.Material and Methods. Sixty patients underwent chemoembolization of the gastroduodenal artery and external beam radiation therapy. Femoral artery angiography was performed using the Seldinger’s technique. Lipiodol 5–7 ml and gemcitabine 400 mg/m2 were used for transarterial chemoembolization. Radiation therapy was given at a total dose of 50 Gy (2 Gy/fraction, 5 times a week, over 5 weeks) using AGAT -R apparatus.Results. Complications after chemoembolization of the gastroduodenal artery were observed in 18.3 % of patients: abdominal pain in 3.3 % of patients; pain and nausea in 3.3 %; pain, nausea and fever in 6.7 %; pain, nausea and increased blood amylase in 1.7 %; pain, nausea and fever, blood amylase in 1.7 %; nausea, fever and blood amylase in 1.7 %. Radiation-induced injuries were observed in 23.3 % of patients: erythema in 18.3 %, grade 1 leukopenia in 1.7% and grade 2 leukopenia in 3.3 %.Conclusion. Complications of neoadjuvant therapy in terms of frequency and severity were consistent with literature data, were manageable with conservative treatment, and did not increase the duration of the preoperative period.

Sign in / Sign up

Export Citation Format

Share Document